DARA BioSciences (NASDAQ:DARA), which earlier this week acquired cancer therapeutics firm Oncogenerix, has made yet another deal, this one an agreement to raise $1.7 million in a private placement.
DARA has reached a definitive agreement with an unnamed institutional investor to sell preferred stock valued at $1.7 million and warrants to purchase 619,308 shares of common stock at $1.31 per share. The warrants expire five years from the date they are issued. DARA expects to close the transaction on Jan. 20.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The securities are being offered in accordance with a shelf-registration statement that was declared effective last April. Raleigh, North Carolina-based DARA says in securities filings that proceeds from the offering will be used for working capital.
DARA has been developing two clinical stage compounds: KRN5500, a treatment for neuropathic pain caused by chemotherapy; and DB959, a type 2 diabetes drug candidate. KRN5500, which has fast-track status from the U.S. Food and Drug Administration, is in phase 2 clinical trials. DB959 is ready to advance into phase 2 clinical trials.
DARA is now positioning itself to market cancer drugs. On Jan. 17, DARA acquired South Carolina specialty pharmaceutical company Oncogenerix in a stock deal. Oncogenerix holds the U.S. rights to Soltamox, a liquid version of breast cancer drug tamoxifen. The acquisition brings DARA its first revenue-generating product. But beyond that Soltamax, DARA is also interested in Oncogenerix’s work on other liquid formulations of cancer drugs as it pursues making generic versions of injectable cancer medicines that are losing patent protection.
Photo from Flickr user stopnlook
